Treatment of the Pinealoma: Experience from a Rare Case Abstract #2930

Introduction: Pinealoma is an extremely rare type of neuroendocrine tumor without evidence-based systemic therapy.
Aim(s): To share our experience of treatment for a patient with pinealoma.
Materials and methods: A 46-year old man, who underwent a surgery because of pinealoma 15 years ago, visited our center because of recurrent high temperature, fatigue and severe anemia. A mass located at the posterior pineal region was found on MRI. 68Ga-DOTANOC-PET/CT and 18F-FDG-PET/CT scan showed that the mass and multiple bone metastasis significantly expressed somatostatin receptors and harbored high uptake of FDG. Immunohistochemistry re-confirmed the surgical specimens as a pinealoma with a Ki-67 index of 1%. Bone marrow biopsy was performed which was further diagnosed as metastatic neuroendocrine tumor. After a multidisciplinary discussion, pinealoma with meninges and bone marrow metastasis was diagnosed, and then 40mg octreotide LAR was injected monthly to control the clinical symptoms. The disease remained stable for 7 months. But CT scan reveled tumor progression 7 months later. Thus, the dosage of octreotide LAR was increased to 60mg/month and interferon alfa (180µg/week) was additionally combined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Jie Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2933 The Clinicopathological Characteristics of Gastrinoma: A Single-Center Retrospective Study
Introduction: Gastrinoma is a rare functional neuroendocrine tumor leading to gastrin hypersecretion and hyperchlorhydria.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Liu M, Chen L, Guo Y, ...
#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report
Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Liu M, Chen L, Guo Y, ...
#2952 Genomic Landscape of Neuroendocrine Neoplasms from Gastrointestinal Tract, Pancreas, Lung, Rare and Unknown Primary Locations
Introduction: There are still few large-scale sequencing data to depict the genomic landscape of neuroendocrine neoplasms (NEN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Professor Jie Chen
Authors: Chen L, Liu M, Zhang Y, Guo Y, ...
#2899 Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China
Introduction: Surgery was the preferred treatment in patients with resectable pancreatic neuroendocrine tumor (pNET), but recurrent lesion relapsed frequently within a short time. It was controversial whether patients with pNET need adjuvant therapy after surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Xiaohan Shi
Authors: Shi X, Xu X, Zhang Y, Gao S, ...
#1434 CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Kaizhou Jin
Authors: Luo G, Guo M, Liu Z, Liu C, ...